机构：[1]Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.[2]Cancer Research Institute, Southern Medical University, Guangzhou, China.[3]Department of pathology, Basic School of Guangzhou Medical University, Guangzhou, China.[4]Department of Neurosurgery, the affiliated hospital of Luzhou medical college, Sichuan, China.[5]Cancer Center, TCM-Integrated Hospital of Southern Medical University, Guangzhou, China.
Although increasing evidence indicated that the deregulation of microRNAs (miRNAs) contributes to tumorigenesis and invasion, little is known about the role of miR-637 in human gliomas. In the present study, we found that the expression level of miR-637 was significantly reduced in clinical glioma tissues compared with normal brain tissues. Moreover, we revealed that the introduction of miR-637 dramatically suppressed glioma cell growth, migration and invasion in vitro and in vivo. Further studies revealed that Akt1 is a direct target gene of miR-637. Silencing of Akt1 inhibited the growth and invasion of glioma cells by decreasing phosphorylated Akt, β-catenin, phosphorylated Foxo1 and Cyclin D1 and inducing the expression of Foxo1, which was consistent with the effect of miR-637 overexpression. Suppressed expression of miR-637 and increased Akt1 protein levels were correlated with unfavorable progression and poor prognosis, respectively, and a negative relationship between the miR-637 expression and Akt1 protein levels was observed in gliomas. Our findings provide new insights into the role of miR-637 in the development of gliomas, and implicate the potential application of miR-637 in cancer therapy.
基金：
National Nature Science Fund of China
(NO.81372692; http://www.nsfc.gov.cn), the Natural Science Fund of Guangdong
Province (NO.S2013010014886; http://www.gdstc.gov.cn), the Medical Scientific
Research Fund of Guangdong Province (NO.B2013238; http://www.medste.gd.cn),
the Scientific Research Initiative Project Fund of Southern Medical University (NO.
B1012032; http://www.fimmu.com), the President Fund of Nanfang Hospital
(2011C007, 2012C011; http://www.nfyy.com), the Science Fund of the Affiliated
Hospital of Luzhou Medical College (2013-60) and Science and Technology Project of
Luzhou (3-S-48).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2015]版：
大类|1 区医学
小类|2 区生化与分子生物学2 区细胞生物学2 区遗传学2 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区遗传学2 区细胞生物学2 区肿瘤学
第一作者：
第一作者机构：[1]Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.[2]Cancer Research Institute, Southern Medical University, Guangzhou, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.[2]Cancer Research Institute, Southern Medical University, Guangzhou, China.[5]Cancer Center, TCM-Integrated Hospital of Southern Medical University, Guangzhou, China.[*1]Department of Neurosurgery, Nanfang Hospital, Southern Medical University, No. 1838, North of Guangzhou Avenue, Guangzhou 510515, China[*2]Cancer Research Institute, Southern Medical University, No. 1838, North of Guangzhou Avenue, Guangzhou 510515, China.
推荐引用方式(GB/T 7714)：
Que T,Song Y,Liu Z,et al.Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1.[J].Oncogene.2015,34(38):4952-63.doi:10.1038/onc.2014.419.
APA：
Que T,Song Y,Liu Z,Zheng S,Long H...&Qi S.(2015).Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1..Oncogene,34,(38)
MLA：
Que T,et al."Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1.".Oncogene 34..38(2015):4952-63
医学